Search Results - "Wouters, Anne K."

Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure by Wachsmann, Tassilo L. A., Wouters, Anne K., Remst, Dennis F. G., Hagedoorn, Renate S., Meeuwsen, Miranda H., van Diest, Eline, Leusen, Jeanette, Kuball, Jürgen, Falkenburg, J. H. Frederik, Heemskerk, Mirjam H. M.

“…Chimeric antigen receptor (CAR) T cell therapies have resulted in profound clinical responses in the treatment of CD19-positive hematological malignancies, but…”
Get full text

Preclinical Strategies to Identify Off-Target Toxicity of High-Affinity TCRs by Bijen, Helena M., van der Steen, Dirk M., Hagedoorn, Renate S., Wouters, Anne K., Wooldridge, Linda, Falkenburg, J.H. Frederik, Heemskerk, Mirjam H.M.

“…Adoptive transfer of T cells engineered with a cancer-specific T cell receptor (TCR) has demonstrated clinical benefit. However, the risk for off-target…”
Get full text

SARS-CoV-2-specific CD4 + and CD8 + T cell responses can originate from cross-reactive CMV-specific T cells by Pothast, Cilia R, Dijkland, Romy C, Thaler, Melissa, Hagedoorn, Renate S, Kester, Michel G D, Wouters, Anne K, Hiemstra, Pieter S, van Hemert, Martijn J, Gras, Stephanie, Falkenburg, J H Frederik, Heemskerk, Mirjam H M

“…Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) specific CD4 and CD8 T cells in SARS-CoV-2-unexposed donors has been explained by the…”
Get full text

Self-sufficient primary natural killer cells engineered to express T cell receptors and interleukin-15 exhibit improved effector function and persistence by van Hees, Els P, Morton, Laura T, Remst, Dennis F G, Wouters, Anne K, Van den Eynde, Astrid, Falkenburg, J H Frederik, Heemskerk, Mirjam H M

“…NK cells can be genetically engineered to express a transgenic T-cell receptor (TCR). This approach offers an alternative strategy to target heterogenous…”
Get full text

PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer by van Amerongen, Rosa A, Tuit, Sander, Wouters, Anne K, van de Meent, Marian, Siekman, Sterre L, Meeuwsen, Miranda H, Wachsmann, Tassilo L A, Remst, Dennis F G, Hagedoorn, Renate S, van der Steen, Dirk M, de Ru, Arnoud H, Verdegaal, Els M E, van Veelen, Peter A, Falkenburg, J H Frederik, Heemskerk, Mirjam H M

“…Recurrent disease emerges in the majority of patients with ovarian cancer (OVCA). Adoptive T-cell therapies with T-cell receptors (TCRs) targeting…”
Get full text

Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain by Meeuwsen, Miranda H, Wouters, Anne K, Wachsmann, Tassilo L A, Hagedoorn, Renate S, Kester, Michel G D, Remst, Dennis F G, van der Steen, Dirk M, de Ru, Arnoud H, van Hees, Els P, Kremer, Martijn, Griffioen, Marieke, van Veelen, Peter A, Falkenburg, J H Frederik, Heemskerk, Mirjam H M

“…The immunoglobulin J chain (Jchain) is highly expressed in the majority of multiple myeloma (MM), and Jchain-derived peptides presented in HLA molecules may be…”
Get full text

T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion by Morton, Laura T, Wachsmann, Tassilo L A, Meeuwsen, Miranda H, Wouters, Anne K, Remst, Dennis F G, van Loenen, Marleen M, Falkenburg, J H Frederik, Heemskerk, Mirjam H M

“…BackgroundT cell receptor (TCR)-engineered cells can be powerful tools in the treatment of malignancies. However, tumor resistance by Human Leukocyte antigen…”
Get full text

WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma by van Amerongen, Rosa A, Hagedoorn, Renate S, Remst, Dennis F G, Assendelft, Danique C, van der Steen, Dirk M, Wouters, Anne K, van de Meent, Marian, Kester, Michel G D, de Ru, Arnoud H, Griffioen, Marieke, van Veelen, Peter A, Falkenburg, J H Frederik, Heemskerk, Mirjam H M

“…BackgroundTranscription factor Wilms’ tumor gene 1 (WT1) is an ideal tumor target based on its expression in a wide range of tumors, low-level expression in…”
Get full text

Targeting epigenetic regulation and post-translational modification with 5-Aza-2’ deoxycytidine and SUMO E1 inhibition augments T-cell receptor therapy by Kroonen, Jessie S, Wouters, Anne K, de Graaf, Ilona J, Remst, Dennis F G, Kumar, Sumit, Wachsmann, Tassilo L A, Teunisse, Amina F A S, Roelands, Jessica P, de Miranda, Noel F C C, Griffioen, Marieke, Heemskerk, Mirjam H M, Vertegaal, Alfred C O

“…BackgroundCellular immunotherapy using modified T cells offers new avenues for cancer treatment. T-cell receptor (TCR) engineering of CD8 T cells enables these…”
Get full text

A library of cancer testis specific T cell receptors for T cell receptor gene therapy by de Rooij, Marije A.J., Remst, Dennis F.G., van der Steen, Dirk M., Wouters, Anne K., Hagedoorn, Renate S., Kester, Michel G.D., Meeuwsen, Miranda H., Wachsmann, Tassilo L.A., de Ru, Arnoud H., van Veelen, Peter A., Verdegaal, Els M.E., Falkenburg, J.H. Frederik, Heemskerk, Mirjam H.M.

“…To increase the number of cancer patients that can be treated with T cell receptor (TCR) gene therapy, we aimed to identify a set of high-affinity…”
Get full text

Simultaneous Deletion of Endogenous TCRαβ for TCR Gene Therapy Creates an Improved and Safe Cellular Therapeutic by Morton, Laura T., Reijmers, Rogier M., Wouters, Anne K., Kweekel, Christiaan, Remst, Dennis F.G., Pothast, Cilia R., Falkenburg, J.H. Frederik, Heemskerk, Mirjam H.M.

“…Generation of an optimal T cell therapeutic expressing high frequencies of transgenic T cell receptor (tgTCR) is essential for improving TCR gene therapy. Upon…”
Get full text

Inhibition of SUMOylation enhances DNA hypomethylating drug efficacy to reduce outgrowth of hematopoietic malignancies by Kroonen, Jessie S., de Graaf, Ilona J., Kumar, Sumit, Remst, Dennis F. G., Wouters, Anne K., Heemskerk, Mirjam H. M., Vertegaal, Alfred C. O.

“…Combination therapies targeting malignancies aim to increase treatment efficacy and reduce toxicity. Hypomethylating drug 5-Aza-2’-deoxycytidine (5-Aza-2’)…”
Get full text

A broad and systematic approach to identify B cell malignancy-targeting TCRs for multi-antigen-based T cell therapy by Meeuwsen, Miranda H., Wouters, Anne K., Jahn, Lorenz, Hagedoorn, Renate S., Kester, Michel G.D., Remst, Dennis F.G., Morton, Laura T., van der Steen, Dirk M., Kweekel, Christiaan, de Ru, Arnoud H., Griffioen, Marieke, van Veelen, Peter A., Falkenburg, J.H. Frederik, Heemskerk, Mirjam H.M.

“…CAR T cell therapy has shown great promise for the treatment of B cell malignancies. However, antigen-negative escape variants often cause disease relapse,…”
Get full text

Cutting Edge: Unconventional CD8 + T Cell Recognition of a Naturally Occurring HLA-A02:01-Restricted 20mer Epitope by Meeuwsen, Miranda H, Wouters, Anne K, Hagedoorn, Renate S, Kester, Michel G D, Remst, Dennis F G, van der Steen, Dirk M, de Ru, Arnoud, van Veelen, Peter A, Rossjohn, Jamie, Gras, Stephanie, Falkenburg, J H Frederik, Heemskerk, Mirjam H M

“…Unconventional HLA class I-restricted CD8 T cell epitopes, longer than 10 aa, have been implicated to play a role in human immunity against viruses and cancer…”
Get full text

Combining BCMA-targeting CAR T cells with TCR-engineered T-cell therapy to prevent immune escape of multiple myeloma by Wachsmann, Tassilo L. A., Meeuwsen, Miranda H., Remst, Dennis F. G., Buchner, Karen, Wouters, Anne K., Hagedoorn, Renate S., Falkenburg, J. H. Frederik, Heemskerk, Mirjam H. M.

Get full text

A library of cancer testis specific T cell receptors for T cell receptor gene therapy by de Rooij, Marije A.J., Remst, Dennis F.G., van der Steen, Dirk M., Wouters, Anne K., Hagedoorn, Renate S., Kester, Michel G.D., Meeuwsen, Miranda H., Wachsmann, Tassilo L.A., de Ru, Arnoud H., van Veelen, Peter A., Verdegaal, Els M.E., Falkenburg, J.H. Frederik, Heemskerk, Mirjam H.M.

Get full text

T Cell Receptor-Based Targeting of Immunoglobulin Constant Domains for Treatment of Multiple Myeloma by Meeuwsen, Miranda H., Wouters, Anne K., Wachsmann, Tassilo L.A., Hagedoorn, Renate S., Remst, Dennis F.G., Kester, Michel G.D., van der Steen, Dirk M., de Ru, Arnoud H., van Veelen, Peter A., Falkenburg, J.H. Frederik, Heemskerk, Mirjam H.M.

Get full text

Sars-Cov-2-Specific CD4+ and CD8+ T Cell Responses Can Originate from Cross-Reactive CMV-Specific T Cells by Pothast, Cilia R., Dijkland, Romy C., Thaler, Melissa, Hagedoorn, Renate S., Kester, Michel G.D., Wouters, Anne K., Hiemstra, Pieter S., van Hemert, Martijn J., Gras, Stephanie, Falkenburg, J.H. Frederik, Heemskerk, Mirjam H.M.

Get full text

Broadly Applicable TCR Based Therapy for Multiple Myeloma Targeting the Jchain by Meeuwsen, Miranda H., Wouters, Anne K., Wachsmann, Tassilo L.A., Hagedoorn, Renate S., Kester, Michel G.D., Remst, Dennis F.G., van der Steen, Dirk M., de Ru, Arnoud H., van Hees, Els P., Griffioen, Marieke, van Veelen, Peter A., Falkenburg, J.H. Frederik, Heemskerk, Mirjam H.M.

Get full text

Combining BCMA-targeting CAR-T with TCR-engineered T-cell therapy to prevent immune escape of multiple myeloma by Wachsmann, Tassilo L A, Meeuwsen, Miranda H, Remst, Dennis F G, Buchner, Karen, Wouters, Anne K, Hagedoorn, Renate, Falkenburg, J H Frederik, Heemskerk, Mirjam H M

“…Chimeric antigen receptor (CAR) T cell therapy targeting BCMA can induce deep remissions in relapsed/refractory multiple myeloma (MM), however, relapse due to…”
Get full text